Analyst at Liberum Capital Maintains The RELX Plc (LON:REL) Buy Rating They’ve Had

June 19, 2018 - By Marry Poplack

RELX PLC (LON:REL) Logo

RELX Plc (LON:REL) Rating Reaffirmed

In a research note issued to investors and clients by Liberum Capital on Tuesday, 19 June, The Rating on RELX Plc (LON:REL) shares of a ‘Buy’ was reaffirmed.

RELX PLC (LON:REL) Ratings Coverage

Among 11 analysts covering RELX Plc (LON:REL), 8 have Buy rating, 0 Sell and 3 Hold. Therefore 73% are positive. RELX Plc has GBX 1990 highest and GBX 1550 lowest target. GBX 1770.45’s average target is 9.49% above currents GBX 1617 stock price. RELX Plc had 22 analyst reports since January 15, 2018 according to SRatingsIntel. Investec maintained the stock with “Buy” rating in Monday, February 12 report. The company was maintained on Monday, March 5 by Liberum Capital. The stock has “Equal Weight” rating by Barclays Capital on Monday, February 12. The stock has “Buy” rating by Deutsche Bank on Friday, February 16. The stock of RELX PLC (LON:REL) earned “Buy” rating by Liberum Capital on Monday, February 19. Barclays Capital maintained the stock with “Overweight” rating in Monday, January 29 report. The stock of RELX PLC (LON:REL) earned “Buy” rating by Goldman Sachs on Friday, February 16. The stock has “Buy” rating by Goldman Sachs on Tuesday, February 13. The stock of RELX PLC (LON:REL) earned “Overweight” rating by JP Morgan on Tuesday, February 13. The company was maintained on Friday, April 6 by Deutsche Bank.

The stock decreased 0.31% or GBX 5 during the last trading session, reaching GBX 1617. About 888,540 shares traded. RELX PLC (LON:REL) has 0.00% since June 19, 2017 and is . It has underperformed by 12.57% the S&P500.

RELX PLC provides information and analytics for professional and business clients in North America, Europe, and internationally. The company has market cap of 31.93 billion GBP. The company's Scientific, Technical & Medical segment offers information, analytics, and tools that help clients make decisions. It has a 19.84 P/E ratio. This segment provides research, reference, and education content; and database and decision tools for scientists, academic institutions, educators, research leaders and administrators, medical researchers, doctors, nurses, and allied health professionals and students, as well as hospitals, research institutions, health insurers, managed healthcare organizations, research-intensive firms, and governments.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: